Cohance Lifesciences Share Price
461.30+0.45 (+0.10%)
-49.03% past 1 Year
News
Cohance Lifesciences to host analyst and investor meeting on September 1
Equity
COHANCE
Cohance Lifesciences sees Rs 46.35 crore BSE block trade at Rs 463.5
Equity
COHANCE
Goldman Sachs retains Buy on Cohance, sees recovery from Q2FY27
Equity
COHANCE
Cohance Lifesciences gets US FDA 483 with five observations at Hyderabad facility
Equity
COHANCE
Cohance Lifesciences Q1 EBITDA collapses sharply with margin erosion year-on-year
Equity
COHANCE
Cohance Lifesciences reports lower Q1 revenue at Rs 422 crores
Equity
COHANCE
Cohance Lifesciences narrows Q1 consolidated net loss on yearly basis
Equity
COHANCE
Jefferies Downgrades Cohance Life to Underperform, Cuts Target to Rs 300 on Weak Q4, Management Churn.
Equity
COHANCE
Cohance Lifesciences - Quaterly Results
Equity
COHANCE
Cohance Lifesciences Q4 EBITDA Declines to Rs 98.50 Crores, Margin Contracts to 15.92%
Equity
COHANCE
Cohance Lifesciences Q4 Results: Sharp YoY Profit and Revenue Decline
Equity
COHANCE
Cohance Lifesciences reports Profit after tax of 34.56 Crores, in the March 2026 quarter
Equity
COHANCE
Cohance Lifesciences informs about press release
Equity
COHANCE
Cohance Lifesciences Appoints Former Cipla CEO Umang Vohra as Executive Chairman & Group CEO.
Equity
COHANCE
Cohance Lifesciences Sees Rs 216 Cr Block Deal for 1.83% Stake, Shares Rally 11%.
Equity
COHANCE
Cohance Lifesciences informs about investor conference
Equity
COHANCE
Cohance Life Sciences Rs 207.89 Cr NSE Block Trade for 67.28 Lakh Shares at Rs 309.
Equity
COHANCE
Cohance Lifesciences Reaffirms Mid-Term Margin Guidance of 30%+ Amid Current Pressures.
Equity
COHANCE
Cohance Lifesciences Withholds FY27 Growth Guidance Amid FY26 Caution in Concall.
Equity
COHANCE
Cohance Lifesciences Retains FY30 Rs 100 Crores Sales Target Amid FY26 Challenges.
Equity
COHANCE